GlassScriptPhysician profile
Scott M Nadel
NPI 1609830587
$2,437.12
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,293 · 2020: $144.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $548.77 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $349.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $289.98 | 2019-2020 | |
| Insmed, INC. | $235.39 | 2019 | |
| Sunovion Pharmaceuticals INC. | $188.44 | 2019 | |
| Genentech USA, INC. | $170.78 | 2019 | |
| Merck Sharp & Dohme LLC | $166.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $109.58 | 2019-2020 | |
| Philips North America LLC | $89.97 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $76.40 | 2019-2020 | |
| Grifols USA, LLC | $69.00 | 2019 | |
| La Jolla Pharmaceutical Company | $47.06 | 2019-2020 | |
| Mylan Specialty L.P. | $34.41 | 2019 | |
| Electromed, INC. | $13.80 | 2019 | |
| Genzyme Corporation | $12.88 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $11.68 | 2019 | |
| Circassia INC. | $11.43 | 2019 | |
| Allergan, INC. | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Nadel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.